Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase -Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) in Patients Aged <18 Years with Primary Immunodeficiency Diseases (PID)

被引：0

作者：

Wasserman, Richard L. ^{[1
]}

Melamed, Isaac ^{[2
]}

Stein, Mark ^{[3
]}

Kobrynski, Lisa ^{[4
]}

Gupta, Sudhir ^{[5
]}

Engl, Werner ^{[6
]}

McCoy, Barbara ^{[7
]}

Leibl, Heinz ^{[6
]}

Yel, Leman ^{[7
]}

机构：

[1] Allergy Partners North Texas Res, Dallas, TX USA

[2] IMMUNOe Hlth Ctr, Centennial, CO USA

[3] Allergy Associates Palm Beaches, North Palm Beach, FL USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Univ Calif Irvine, Irvine, CA USA

[6] Shire, Vienna, Austria

[7] Shire, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2017年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

PO - 135

引用

页码：S53 / S54

页数：2

共 50 条

[21] LONG-TERM SAFETY AND PHARMACOKINETICS OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): PHASE 3 EXTENSION STUDY IN PRIMARY IMMUNODEFICIENCY DISEASE
Melamed, I.
Wasserman, R. L.
Stein, M.
Rubenstein, A.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 132 - 133
[22] LONG-TERM EFFICACY OF RECOMBINANT HUMAN HYALURONIDASE (RHUPH20)-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (IGHY; HYQVIA) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID): INFECTION RATES OVER THE COURSE OF TREATMENT
Wasserman, R. L.
Stein, M.
Kobrynski, L.
Gupta, S.
Grant, J.
Rubinstein, A.
Engl, W.
Mccoy, B.
Leibl, H.
Yel, L.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A102 - A102
[23] MECHANISM OF ACTION AND LONG-TERM TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNE GLOBULIN 10% (HYQVIA [IGHY]) IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)
Melamed, Isaac
Gupta, Sudhir
Sehinovych, Ihor
Hermann, Corinna
Engl, Werner
McCoy, Barbara
Leibl, Heinz
Yel, Leman
MUSCLE & NERVE, 2018, 58 : S50 - S50
[24] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF IMMUNE GLOBULIN (HUMAN), 10% AND RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASE (PIDD)
Stein, M.
Wasserman, R. L.
Melamed, I.
Rubinstein, A.
Engl, W.
Leibl, H.
McCoy, B.
Gelmont, D.
Schiff, R. I.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A95 - A95
[25] Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human) 10% AND Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients with Primary Immunodeficiency (PI)
Wasserman, Richard
Melamed, Isaac
Stein, Mark
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
Gelmont, David
Schiff, Richard
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 367 - 367
[26] RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNO GLOBULIN G (IGG) (HYQVIA; IGHY) IN PATIENTS AGED ≥16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PI): LONG TERM SAFETY, EFFICACY, AND TOLERABILITY.
Wasserman, R. L.
Stein, M.
Melamed, I.
Kobrynski, L.
Grant, J. A.
Gupta, S.
Engl, W.
Leibl, H.
Yel, L.
Schiff, R. I.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A89 - A89
[27] Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)
Wasserman, R. L.
Melamed, I.
Stein, M.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB15 - AB15
[28] Long-term safety of facilitated subcutaneous immunoglobulin: Insights from a postauthorization safety study in primary immunodeficiency diseases (PID)
Rubinstein, Arye
Patel, Niraj C.
Wedner, H. James
Wasserman, Richard L.
Gupta, Sudhir
Fielhauer, Katharina
Chavan, Shailesh
Yel, Leman
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2021, 26 (03) : 334 - 335
[29] EUROPEAN POSTAUTHORIZATION SAFETY STUDY ON LONG-TERM HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN IN PRIMARY IMMUNODEFICIENCY DISEASES: INTERIM ANALYSIS
Ellerbroek, Pauline M.
van Paassen, Pieter
Hanitsch, Leif
Plebani, Alessandro
Schmidt, Reinhold E.
van Hagen, P. Martin
Wang, Ping
Fielhauer, Katharina
Leibl, Heinz
Chavan, Shailesh
Yel, Leman
MUSCLE & NERVE, 2020, 62 : S67 - S68
[30] Real-World Use of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IG) (IGHy) in Patients with Primary Immunodeficiency Disorders (PIDD)
Rosenbach, Kevin P.
Hughes, Stephanie
Rozen, Leon
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB220 - AB220

← 1 2 3 4 5 →

Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase -Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) in Patients Aged &lt;18 Years with Primary Immunodeficiency Diseases (PID)

Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase -Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) in Patients Aged <18 Years with Primary Immunodeficiency Diseases (PID)